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Abstract
Background: Neuropathic-like knee pain (NKP) is often reported in individuals with knee pain (KP), but the contribution of
specific central and peripheral risk factors to NKP has not been studied previously. The aims of the present study were to
determine the prevalence of NKP in a community-derived sample with KP and to identify risk factors associated with NKP.
Methods: A cross-sectional study was undertaken (n = 9506) in the East Midlands community among responders (aged 40
+ years) to a postal questionnaire. Questions included KP severity (numerical rating scale) and type (neuropathic versus
nociceptive) using the modified painDETECT questionnaire, as well as age, body mass index (BMI), significant knee injury,
widespread pain, pain catastrophising and fatigue. Multinomial regression analysis was used to determine ORs and 95% CIs.
Risk factors were categorised into central and peripheral, and proportional risk contribution (PRC) and 95% CI were
estimated using ROC.
Results: KP was reported in 28.2% of responders, of whom 13.65% had NKP (i.e., 3.9% of the total population). Women
reported more NKP. After adjustment for age, gender, BMI and pain severity, definite NKP showed associations
(aOR, 95% CI) with fibromyalgia (4.07, 2.49–6.66), widespread pain (1.93, 1.46–2.53), nodal osteoarthritis (1.80, 1.28–2.53),
injury (1.50, 1.12–2.00), pain catastrophising (5.37, 2.93–9.84) and fatigue (5.37, 3.08–9.35) compared with non-NKP
participants. Although only central risk factors contributed to NKP (PRC 8%, 95% CI 2.5–12.5 for central vs. PRC 3%, 95%
CI −0.25 to 7.5 for peripheral), both central and peripheral risk factors contributed equally to non-NKP (PRC 10%, 95%
CI 5–20 for both).
Conclusions: NKP appears to be driven largely by central risk factors and may require different prevention/treatment
strategies.
Trial registration: ClinicalTrials.gov, NCT02098070. Registered on 27 March 2014.
Keywords: Neuropathic pain, Osteoarthritis, Risk factors, Pain catastrophising, Anxiety, Depression
Background
Knee pain (KP) is a major cause of disability worldwide. In
the United Kingdom (UK) approximately 1 in 4 people
aged 55 years and over report prevalent KP [1]. KP is often
attributed to localised tissue insult that causes nociceptive
pain. However, recent data suggest that localised damage
to the nervous system and nerve fibres around a joint
could result in neuropathic-like knee pain (NKP) that
modifies the KP experience [2]. KP can also be modified
by central sensitisation following chronic nociceptor
stimulation and alterations in central pain transmitting
neurons and can result in NKP characteristics [3]. This
could be induced by localised insult to the joint, by co-
morbid conditions or by psychological factors that modify
pain physiology and descending pain modulation. How-
ever, such modifying factors are rarely studied and are
often omitted in clinical assessments of KP [4].
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KP can be broadly categorised into nociceptive
(inflammatory or mechanical local mechanisms); neuro-
pathic, involving nerve damage (and potentially involving
central mechanisms); and idiopathic pain with no identi-
fied cause (presumably driven predominantly by central
factors) [5]. Being able to correctly identify different types
of KP could have implications for treatment selection and
management pathways. KP is the main complaint of knee
osteoarthritis (KOA) [6] and is the primary reason pa-
tients seek treatment. As Hadler eloquently wrote, ‘Knee
pain is the malady, not osteoarthritis’ [7]. Furthermore,
half of those who complain of KP have no definite radio-
graphic evidence of KOA [8], and 20% of people with
KOA have persistent severe KP even after total knee re-
placement [9]. These findings suggest that central factors
other than severity of local structural KOA influence KP
experience and that identifying and addressing these cen-
tral factors associated with NKP features, particularly early
in the disease, could benefit people with such KP.
NKP associates with characteristic symptoms and pain
qualities, including burning pain, tingling or prickling,
mechanical and thermal hyperalgesia, allodynia, paroxysmal
pain and numbness. Although quantitative sensory testing
(QST) is helpful in confirming abnormal pain thresholds,
this is impractical for widespread use within a community
setting [10]. There are a number of screening tools and
questionnaires, such as the SLANNS, painDETECT ques-
tionnaire (PDQ) and DN4 (Douleur Neuropathique 4), that
use descriptions of pain location, intensity, frequency and
pain quality to determine whether pain is likely to be
neuropathic or nociceptive [11, 12]. The PDQ was subse-
quently modified (mPDQ) for use in specific areas of the
body, such as the knee, with good face and content validity
and good correlation with QST signs of central sensitisation
[13, 14]. Hochman et al. [10] reported that one-third of par-
ticipants with KOA (n = 259) described their pain using
neuropathic descriptors and were more likely to be younger
and female, with higher pain and osteoarthritis (OA) sever-
ity as well as longer OA duration, than those who did not
use such descriptors. The research suggests the existence of
subgroups of participants with shared characteristics that
exhibit NKP symptoms. Should that be the case, target-
ing treatment to the underlying pain mechanism
could have the potential to improve pain management
and to improve quality of life with individualised
treatment interventions. The objectives of this study
were to (1) determine the prevalence of NKP in
community-derived people with KP and (2) identify
risk factors specifically associated with NKP.
Methods
Study design
The Nottingham Knee Pain and Health in the Community
(KPIC) study is an ongoing prospective cohort study in
the East Midlands region of the UK [15]. The current
study used baseline KPIC data to identify people with KP
and the proportion of those who reported NKP. A
case-control study was conducted with three groups: NKP,
non-NKP and no KP. The study was approved by the
Nottingham Research Ethics Committee 1 (NREC refer-
ence 14/EM/0015) and registered with ClinicalTrials.gov
(NCT02098070).
Sample size
Source population
The survey comprised a community-derived sample re-
gardless of whether subjects had experienced KP. A pos-
tal questionnaire was developed on the basis of a review
of items in previously published questionnaires [16, 17].
Further details on questionnaire logistics and sample size
calculations have been published previously [15].
NKP prevalence and risk factors
According to a NKP prevalence in people with KP of 28%
(±8%) based on a Canadian community population sample
[10], a minimum of 85 participants with KP were required
to yield a power of 90% with a 0.05 significance level.
Participants
Inclusion criteria
The inclusion criteria were all men and women aged
40 years and over, located on their general practitioner
(GP) register, regardless of KP status.
Exclusion criteria
Exclusion criteria were inability to give informed consent
and presence of a terminal illness or severe mental illness.
Eligibility was decided by the GPs in each practice. The ques-
tionnaire was accompanied by a covering letter from the GP
introducing the study and its objectives. Return of a com-
pleted questionnaire in a pre-paid envelope to Academic
Rheumatology (City Hospital, Nottingham) was taken as im-
plicit consent.
Questionnaire survey
The questionnaire was constructed to capture detailed infor-
mation about the participants, as well as their medical his-
tory and risk factors for KOA [18]. A validated screening
question was used to determine presence of current KP:
‘Have you ever had knee pain for most days of the past one
month?’ [19, 20]. Additionally, a body pain manikin [21] was
used to locate and define pain in other body regions, allow-
ing definition of widespread pain based on criteria proposed
by the American College of Rheumatology which require
presence of pain in all four quadrants as well as the axial
skeleton [22]. The mPDQ was chosen to identify NKP
(PDQ scores ≥ 13 as possible NKP and ≥ 19 as definite
NKP) [13]. On the basis of face validity of the questionnaire
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content, previous literature [23] and consensus among the
authors, the data on risk factors obtained from the question-
naire were divided into three groups: peripheral (related to
structural changes in and around the knee joint, such as sig-
nificant injury and nodal OA [which associates with
likelihood of structural KOA]), central (related to pain ex-
perience and physiology such as anxiety, depression, fatigue,
Pain Catastrophising Scale [PCS] and self-reported
GP-diagnosed fibromyalgia) and comorbidities (such as
hyperlipidaemia, diabetes and widespread pain as defined
using the body pain manikin [15]). Further details on each
exposure measured included KP severity, constitutional knee
alignment, nodal OA, 2D:4D (index:ring) digit ratio, anxiety,
depression, fatigue and pain catastrophising, and high-risk
occupations can be found in the published study protocol
[15]. Exposures such as 2D:4D digit ratio and nodal OA are
recognised risk factors for knee pain and knee OA [1, 13,
15] and were included in order to identify as many possible
associations and confounders as possible [10, 13, 14].
Statistical analyses
Categorical variables were reported as frequencies and
continuous variables as mean and SD. OR and 95% CI
were calculated using multinomial logistic regression for
three-group comparisons (NKP, non-NKP and no KP).
Each risk factor was adjusted for the same confounding
factors (age, body mass index [BMI], gender and pain se-
verity). Statistical significance was defined as p < 0.05.
There were very few missing data at random (e.g., where
BMI was not reported by a participant), so imputation or
modelling was not undertaken for occasional missing
values. All variables were reported as dichotomous data,
with the exception of PCS and fatigue scores. PCS was re-
ported as per official cut-offs in tertiles (< 18 [lowest ter-
tile], 18–24 [middle tertile], ≥24 [highest tertile]). Fatigue
data were reported using a Likert-style scale and were
categorised as lowest tertile (never), middle tertile (seldom
and sometimes) and highest tertile (often and always).
We also used ROC to calculate AUC, from which pro-
portional risk contribution (PRC) of central risk factors,
peripheral risk factors and comorbidities was derived. ROC
curves were based on the multivariate logistic regression
model with definite NKP as an outcome compared with
non-NKP. Firstly, we built the full risk model for definite
NKP with an ROC curve (ROC1). Secondly, we removed
the exposure(s) of interest to examine the contribution of
the exposure(s) through the reduction of the ROC curve
(i.e., the partial ROC [ROC2]). Thirdly, we calculated the
PRC using the following formula:
PRC ¼ ROC1−ROC2½ = ROC1−0:5½ 
The 95% CI of PRC was calculated according to 95% CIs
of ROC1 and ROC2. We also calculated ROC curves based
on non-NKP as an outcome compared with no KP to deter-
mine the PRC of peripheral and central risk factors and co-
morbidities. PRCs for each of the groups (central and
peripheral risk factors and comorbidities) indicate the contri-
bution of each to the outcome of definite NKP. The ROC
curves were generated using STATA software (StataCorp,
College Station, TX, USA) with the roctab command and
combined graphically [24]. All analysis was conducted using
Stata IC version 14 on the Windows 7 operating system, and
power calculations were undertaken using Power and Preci-
sion version 2.1 software (Biostat, Englewood, NJ, USA).
Results
Of the 40,505 mailed questionnaires, 9506 (23.4%) com-
pleted questionnaires were returned which met the inclu-
sion criteria. The characteristics of these participants were
compared with those from other national UK cohorts
(Appendix). The data showed that the KPIC population is
representative of the UK general population in terms of
age, percentage of women and BMI (Appendix).
Of the responders, 2681 participants (28.3%) reported
KP for most days of the past month. Of these KP partici-
pants, 366 (13.65% of those with KP, 3.9% of the total
KPIC) had NKP. Proportions of 16.6% of women with KP
and 11.6% of men with KP reported definite NKP. Women
also reported more NKP in almost every age category than
men and peaked 10 years later in the age range of 60–
64 years than men in the age range of 50–54 years (Fig. 1).
Comparison of the participants in the four categories
(definite NKP, possible NKP, non-NKP and no KP) showed
that those with definite NKP were more likely to be youn-
ger, female and have greater BMI (p < 0.01). They were also
more likely to self-report a diagnosis of fibromyalgia, hyper-
tension, hyperlipidaemia and diabetes; report significant
knee injury; work in high-risk occupations; present with
nodal OA and widespread pain; and have higher scores for
anxiety and depression than people without KP (p < 0.001).
These results are presented in Table 1.
We compared definite NKP participants with no-KP par-
ticipants to determine which factors were associated with
definite neuropathic-like symptoms compared with no KP.
Unadjusted and adjusted ORs (for age, BMI, gender and pain
severity) for definite NKP compared with no-KP participants
were calculated for each risk factor (Table 2). The results of
the multinomial regression analysis comparing NKP with no
KP showed significant associations, particularly for central
factors such as fibromyalgia (aOR 3.19, 95% CI 1.70–5.98),
anxiety (aOR 2.48, 95% CI 1.76–3.48), depression (aOR 2.62,
95% CI 1.70–4.04), highest tertile of pain catastrophising
(aOR 5.00, 95% CI 2.68–9.36) and highest tertile of fatigue
(aOR 5.11, 95% CI 2.86–9.15) (Table 2). The most
significant result for peripheral risk factors was
significant knee injury and the presence of nodal OA
(1.44 [1.04–1.99] and 1.76 [1.19–2.63], respectively).
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We compared definite NKP participants with non-NKP
participants to determine which factors were associated
with definite neuropathic-like symptoms compared with
non-neuropathic-like knee pain. Unadjusted and adjusted
ORs for definite NKP versus non-NKP were also calcu-
lated for each risk factor (Table 3). After adjustment for
age, BMI, gender and KP severity, definite NKP was sig-
nificantly associated with two peripheral risk factors
(injuries [aOR 1.50, 95% CI 1.12–2.00] and nodal OA
[aOR 1.80, 95% CI 1.28–2.53]) and all measured central
risk factors (fibromyalgia [aOR 4.07, 95% CI 2.49–6.66],
anxiety [aOR 3.17, 95% CI 2.38–4.23], depression [aOR
2.99, 95% CI 2.14–4.19], pain catastrophising [aOR 5.37,
95% CI 2.93–9.84] and fatigue [aOR 5.37, 95% CI
3.08–9.35]). There were also associations with markers
of metabolic syndrome, such as diabetes (aOR 1.52,
95% CI 1.04–2.23) and hyperlipidaemia (aOR 1.36,
95% CI 1.01–1.84).
Fig. 1 The prevalence of definite neuropathic-like knee pain in the knee pain population in Nottingham Knee Pain and Health in the Community
study, by gender and in age categories
Table 1 Comparison of all characteristics of four groups within the Nottingham Knee Pain and Health in the Community study community
Characteristics No KP (n = 6822) Non-NKP (n = 1685) Possible NKP (n = 462) Definite NKP (n = 366) P value
Age, yr, mean (±SD) 62.12 (10.64) 61.94 (10.41) 61.80 (10.32) 61.13 (9.96) 0.03*
Body mass index, kg/m2, mean (±SD) 26.61 (4.76) 28.30 (5.42) 29.84 (6.39) 31.49 (7.77) < 0.001*
Female gender, n (%) 3806 (55.80.09) 956 (56.74) 258 (55.84) 242 (66.12) 0.02*
High-risk occupation, n (%) 2660 (38.99) 783 (46.47) 271 (58.66) 193 (52.73)) < 0.001*
Fibromyalgia, n (%) 101 (1.48) 52 (3.09) 26 (5.63) 57 (15.57) < 0.001*
Hypertension, n (%) 1890 (27.70) 555 (32.94) 183 (39.61) 146 (39.89) < 0.001*
High cholesterol, n (%) 1773 (25.99) 495 (29.38) 156 (33.77) 143 (39.07)) < 0.001*
Stroke, n (%) 174 (2.55) 51 (3.02) 14 (3.03) 15 (4.10) 0.05
Diabetes, n (%) 550 (8.06) 172 (10.21) 72 (15.58) 73 (19.95)) < 0.001*
2D:4D digit ratio, n (%) 3256 (47.73) 792 (47.00) 232 (50.22) 142 (38.80) 0.03*
Nodal OA, n (%) 632 (9.62) 234 (14.60) 79 (18.20) 88 (25.36) < 0.001*
Significant injury, n (%) 972 (14.25) 478 (28.38) 165 (35.71) 130 (35.52) < 0.001*
Widespread pain, n (%) 1072 (15.71) 537 (31.87) 209 (45.24) 198 (54.10) < 0.001*
Anxiety, n (%) 754 (11.05) 298 (17.70) 148 (32.03) 191 (52.19) < 0.001*
Depression, n (%) 266 (3.90) 142 (8.43) 91 (19.70) 133 (36.34)) < 0.001*
Abbreviations: KP Knee pain, NKP Neuropathic-like knee pain, OA Osteoarthritis
* is statistical significance <0.05
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Table 3 Regression results of definite neuropathic-like knee pain versus possible- and non-neuropathic-like knee pain
OR (95% CI)
Non-NKP Possible NKP Definite NKP
Crude Adjusted Crude Adjusted
(n = 1685) (n = 462) (n = 366)
Age 1 (Reference) 0.99 (0.99; 1.00) – 0.99 (0.98; 1.00) –
Body mass index 1 1.04 (1.02; 1.06) – 1.08 (1.06; 1.10) –
Gender 1 0.98 (0.79; 1.21) – 1.50 (1.18; 1.91) –
Pain severity 1 1.37 (1.31–1.45) – 2.08 (1.93; 2.25) –
Putative factors
High-risk occupation 1 1.63 (1.33; 2.01) 1.57 (1.24; 1.99) 1.29 (1.03–1.61) 1.17 (0.89; 1.54)
Significant injury 1 1.42 (1.14; 1.77) 1.36 (1.07; 1.73) 1.47 (1.15; 1.88) 1.50 (1.12; 2.00)
2D:4D digit ratio 1 1.00 (0.99; 1.00) 0.99 (0.99; 1.00) 1.00 (0.99; 1.00) 0.99 (0.99; 1.00)
Nodal OA 1 1.30 (0.98; 1.72) 1.34 (0.98; 1.83) 1.99 (1.50; 2.63) 1.80 (1.28; 2.53)
Comorbidities
Hypertension 1 1.34 (1.08; 1.65) 1.18 (0.92; 1.52) 1.35 (1.07; 1.70) 1.09 (0.80; 1.47)
Hyperlipidaemia 1 1.22 (0.98; 1.53) 1.12 (0.86; 1.44) 1.54 (1.22; 1.95) 1.36 (1.01; 1.84)
Stroke 1 1.00 (0.55; 1.83) 0.97 (0.52; 1.84) 1.37 (0.76; 2.46) 0.92 (0.44; 1.92)
Diabetes 1 1.62 (1.20; 2.19) 1.32 (0.94; 1.85) 2.19 (1.62; 2.96) 1.52 (1.04; 2.23)
Multiple regional pain 1 1.76 (1.43; 2.18) 1.63 (1.29; 2.05) 2.52 (2.00; 3.17) 1.93 (1.46; 2.53)
Central factors
Anxiety 1 2.20 (1.74; 2.76) 1.79 (1.38; 2.32) 5.08 (3.99; 6.45) 3.17 (2.38; 4.23)
Depression 1 2.66 (1.99; 3.55) 1.96 (1.42; 2.70) 6.20 (4.71; 8.15) 2.99 (2.14; 4.19)
Pain Catastrophising
Scale
Lowest tertile 1 Reference
Middle tertile 2.46 (1.64; 3.67) 2.03 (1.32; 3.10) 2.01 (1.05; 3.84) 1.31 (0.66; 2.60)
Highest tertile 5.91 (4.05; 8.62) 3.63 (2.40; 5.48) 16.12 (9.12; 28.49) 5.37 (2.93; 9.84)
Fatigue
Lowest tertile 1 Reference
Middle tertile 1.41 (1.03; 1.93) 1.15 (0.82; 1.62) 3.22 (1.89; 5.48) 2.45 (1.38; 4.38)
Highest tertile 2.77 (2.05; 3.75) 1.91 (1.38; 2.66) 11.12 (6.69; 18.47) 5.37 (3.08; 9.35)
Fibromyalgia 1 1.87 (1.16; 3.03) 1.56 (0.92; 2.66) 5.79 (3.90; 8.61) 4.07 (2.49; 6.66)
Treatment
Opioids 1 1.98 (1.54; 2.54) 1.46 (1.11; 1.92) 3.03 (2.35;3.91) 1.70 (1.26; 2.31)
NSAIDs 1 1.22 (0.82; 1.81) 1.01 (0.66; 1.56) 2.03 (1.40; 2.95) 1.75 (1.13; 2.72)
OTC painkillers 1 1.66 (1.33; 2.07) 1.39 (1.09; 1.78) 1.76 (1.38; 2.24) 1.28 (0.96; 1.71)
Aspirin 1 1.31 (0.96; 1.79) 1.12 (0.79; 1.60) 1.66 (1.20; 2.28) 1.40 (0.94; 2.09)
Current statin use 1 0.99 (0.99; 1.00) 0.99 (0.99; 1.00) 0.99 (0.99; 1.00) 1.00 (0.99; 1.00)
Statin use ever 1 0.99 (0.99;0.99) 0.99 (0.99; 1.00) 0.99 (0.99; 0.99) 0.99 (0.99; 1.00)
Injection 1 2.04 (1.59; 2.61) 1.66 (1.27; 2.18) 3.52 (2.74; 4.52) 2.39 (1.76; 3.23)
Pain experience
ICOAP overall 1 1.04 (1.03; 1.05) 1.03 (1.02; 1.04) 1.08 (1.07; 1.09) 1.05 (1.04; 1.07)
ICOAP intermittent 1 1.04 (1.03; 1.04) 1.02 (1.02; 1.03) 1.07 (1.06; 1.08) 1.04 (1.04; 1.05)
ICOAP constant 1 1.04 (1.03; 1.04) 1.05 (1.04; 1.06) 1.07 (1.06; 1.08) 1.05 (1.04; 1.06)
Abbreviations: ICOAP Intermittent and Constant Osteoarthritis Pain measure, NKP Neuropathic-like knee pain, NSAIDs Non-steroidal anti-inflammatory drugs,
OA Osteoarthritis, OTC Over the counter
Non-NKP is non-neuropathic-like knee pain; likely NKP is likely neuropathic pain; and definite NKP is definite neuropathic-like knee pain
The non-KP group is the referent group, and hence a ‘1’ represents this in the table
Note: Significant associations are highlighted in bold. For comparison purposes, we only present crude and age-, gender-, BMI- and pain severity-adjusted
OR for each factor
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The ROC for the full model for definite NKP compared
with non-NKP, including central and peripheral risk factors
and comorbidities was 0.90 (0.88; 0.92) with the PRC of per-
ipheral, central and comorbidity risk factors as 3%, 8% and
3%, respectively. The ROC for the full model for non-NKP
compared with no KP was 0.70 (0.69; 0.72) with the PRC of
peripheral, central and comorbidity risk factors as 10%, 10%
and 5%, respectively. These ROC graphs are presented in
Fig. 2, with further details presented in Table 4.
Discussion
To our knowledge, this is the first community-based study
of the prevalence of NKP and associated risk factors. The
main findings are as follows: (1) the prevalence of NKP in
this sample of people with KP in the Nottingham commu-
nity is 13.65%; (2) the prevalence of NKP is higher in
women and peaks 10 years later than in men; (3) the risk
factors associated with definite NKP compared with
non-NKP are knee injury; nodal OA; central factors such
as depression, anxiety and pain catastrophizing; and co-
morbidities such as diabetes and hyperlipidaemia; and (4)
although contributing factors to NKP are predominantly
central, both central and peripheral risk factors contribute
equally to non-NKP.
a
b
Fig. 2 a Proportional risk contribution (PRC) of peripheral, central and comorbidity risk factors of definite neuropathic-like knee pain (NKP) vs. non-NKP.
b PRC of peripheral, central and comorbidity risk factors of non-NKP vs. no knee pain (KP). Blue= full model. Red = PRC from peripheral factors. Green=
PRC from central factors. Orange = PRC from comorbidities. Note: PRC was estimated from full ROC analysis. Full models included age, gender, body
mass index and pain severity, nodal OA + significant knee injury (peripheral factors), anxiety + depression + Pain Catastrophising Scale, fibromyalgia
and fatigue (central factors) and diabetes + hyperlipidaemia + widespread pain (comorbidities). Pain severity variable was removed from the second
ROC analysis comparing non-NKP vs. no KP participants
Table 4 ROC and 95% CI for risk factor groups comparing
different participants based on neuropathic-like knee pain profile
ROC 95% CI PRC (%) PRC 95% CI
Definite NKP vs. non-NKP
Full* 0.90 0.88; 0.92 100% –
Without peripheral 0.89 0.87; 0.91 3% −2.5; 7.5
Without central 0.87 0.85; 0.89 8% 2.5; 12.5
Without comorbidities 0.89 0.88; 0.91 3% −2.5; 5
Non-NKP vs. no KP
Full 0.70 0.69; 0.72 100% –
Without peripheral 0.68 0.66; 0.69 10% 5; 20
Without central 0.68 0.66; 0.69 10% 5; 20
Without comorbidities 0.69 0.67; 0.70 5% 0; 15
Abbreviations: KP Knee pain, NKP Neuropathic-like knee pain, PRC Proportional
risk contribution
ROC results for the full model including age, gender, body mass index and
pain severity
Peripheral = significant injury, nodal osteoarthritis
Central = anxiety, depression, Pain Catastrophising Scale (by highest tertile),
fatigue, fibromyalgia
Comorbidities: hyperlipidaemia, diabetes, widespread pain
Pain severity was not included from the second ROC analysis comparing non-NKP
with no KP participants
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The prevalence of NKP (13.65%) appears higher than in
previous questionnaire-based population-wide studies
(8.0–8.9%) [25–27]. However, these previous studies defined
the prevalence of NKP in the general population, not in a KP
population specifically. Conversely, prevalence in our study is
also lower than in studies that have reported NKP in symp-
tomatic KOA populations (23%) [28]. This may be because
of factors such as different people at risk (KP versus KP plus
structural KOA), various definitions of NKP, and sample
sizes. In addition to requiring radiographic changes, six of
the nine studies in this systematic review used hospital-based
samples where more severe cases were included, probably
explaining their higher prevalence estimate [29].
Individuals with NKP were more likely to be women
and obese (BMI ≥ 30 kg/m2) than those without NKP.
This accords with previous prevalence studies [29, 30]
reporting higher overall neuropathic pain prevalence in
women of 8–10.2% compared with 6–7.9% in men [25,
31]. The main risk factors associated with NKP are central
factors such as depression, anxiety, pain catastrophising
and fatigue. This is supported by a composite measure—
the PRC—where contribution from the central risk factors
to NKP was greater (8%) than that from peripheral risk
factors (3%), whereas the contributions from central (10%)
and peripheral (10%) risk factors to non-NKP were equal.
It is well known that psychological factors such as depres-
sion can influence pain perception and behaviour [32]. It
is possible that KP, which contributes to functional limita-
tions, fatigue and possible sleep disturbance, may in turn
contribute to lower mood, increased anxiety and worse
pain and functional scores, resulting in a complex
inter-relationship [33, 34].
This study also showed that fibromyalgia and wide-
spread pain were highly associated with NKP in the
community when compared with non-NKP and were
still significantly associated, but to a lesser extent, when
compared with no-KP participants. Fibromyalgia is often
considered a predominantly central ‘top-down’ disorder
driven by psychological distress, sleep disturbance and
symptoms of anxiety and depression [35], whereas those
with neuropathic symptoms have a ‘bottom-up’ disorder
driven by peripheral changes and neurogenic damage
[36]. The association reported in this study indicates the
overlap between these two conditions that share mecha-
nisms of central sensitisation, but causation cannot be
established in a cross-sectional study.
Our study also demonstrated that diabetes associates
with NKP compared with non-NKP, but not when com-
pared with the no-KP group. Although we did not differ-
entiate type 1 and type 2 diabetes, it is plausible that the
metabolic syndrome underlies the onset and progression
of neuropathy and obesity, and its consequences are po-
tential driving adverse factors that propagate altered
nerve functioning and injury [37].
There are several clinical implications of this project.
Whilst KP has often been treated primarily with frontline
analgesic agents, the effect sizes for these drugs are small
and do not improve over time [38]. This study supports
previous findings [39, 40] that there is a neuropathic com-
ponent to KP that is predominantly driven by central pain
sensitisation processes or, more specifically, central risk fac-
tors. Considering that the findings that there is a strong
contribution and association of central factors such as de-
pression, anxiety and pain catastrophising to definite NKP,
these need to be managed correctly in the KP patient popu-
lation and early stages of the OA process.
There are several limitations to this study. Firstly, the use
of self-reported questionnaires might involve recall bias and
possible misclassification of self-reported outcomes. Never-
theless, we used a validated questionnaire and involved pa-
tient and public volunteers to help optimize clarity and ease
of questionnaire use. Secondly, the low response rate (24%)
could have resulted in selection bias because those with KP
may be more motivated to participate. However, a compari-
son of KPIC demographic data was made with other local
and national UK community cohorts (Appendix), which
demonstrated comparability in terms of age, gender distribu-
tion and BMI. Thirdly, whilst the questionnaire covered a
spectrum of risk factors associated with KP and NKP, we did
not measure smoking status, education level or alcohol con-
sumption at baseline. Similarly, we did not have measures of
all potential peripheral risk factors (e.g., radiographic OA
scores, synovitis and muscle strength). These have minimised
the PRC and do not necessarily reflect the real ratio of cen-
tral and peripheral risk factor contributions. Further study
including more comprehensive measurements of both cen-
tral and peripheral risk factors is therefore warranted. Fur-
thermore, widespread pain was included as a comorbidity
rather than as a central factor because it is widely regarded
as such in the literature [41, 42]. However, there are limita-
tions in the understanding of pain physiology, and the
groups in our analysis (central, peripheral and comorbidity
risk factors) may not be entirely mutually exclusive owing to
these overlaps, which is a further caveat to our findings.
Conclusions
In summary, the prevalence of NKP in those with KP in
this community sample is approximately 14%. NKP affects
more women across all age groups. People with central risk
factors such as depression and anxiety and peripheral risk
factors such as injury and comorbidities, particularly dia-
betes, are more likely to have NKP. The results suggest that
of the risk factors examined, NKP is predominantly cen-
trally driven, whereas non-NKP is driven equally by both
peripheral and central factors. Consideration of NKP char-
acteristics and the balance of central versus peripheral risk
factors in individuals with KP could help direct best treat-
ment selection and optimise patient care.
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